BioLight Life Sciences Ltd. (TLV:BOLT)

Market Cap	25.96M
Revenue (ttm)	169.00K
Net Income (ttm)	-12.72M
Shares Out	4.69M
EPS (ttm)	-2.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,352
Average Volume	5,554
Open	553.60
Previous Close	553.60
Day's Range	526.00 - 553.60
52-Week Range	355.00 - 702.00
Beta	0.25
RSI	48.87
Earnings Date	Aug 21, 2025

About BioLight Life Sciences

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company’s ophthalmic product offering and pipeline of product candidates include DiagnosTear’s TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival imp...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 4
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BOLT

Financial Performance

In 2024, BioLight Life Sciences's revenue was 219,000, an increase of 85.59% compared to the previous year's 118,000. Losses were -7.14 million, -72.55% less than in 2023.